ALZpath Inc. signed a global licensing agreement with Abbott Laboratories to develop and commercialize a blood-based test for Alzheimer's disease. The deal provides ALZpath's diagnostic technology with access to Abbott's worldwide distribution network. Financial terms were not disclosed.
ALZpath Inc. licensed its Alzheimer's blood-testing technology to Abbott Laboratories in a global deal, giving the diagnostics giant access to a fast-growing market for easier brain disease detection.
"This partnership combines ALZpath's diagnostic technology with Abbott's global reach to accelerate access to Alzheimer's blood testing," the companies said in a joint statement.
The deal comes as diagnostics companies and pharmaceutical firms race to develop blood-based tests for Alzheimer's, which affects millions worldwide. Current diagnostic methods include costly PET scans and invasive spinal taps, creating demand for simpler blood-based alternatives. Abbott, with operations in more than 160 countries, can distribute the test across hospital systems and clinical laboratories globally.
For Abbott, the partnership strengthens its diagnostics portfolio in neurology, a high-growth segment where early detection tools are becoming critical as new Alzheimer's treatments enter the market. The global Alzheimer's drug market is projected to grow substantially as disease-modifying therapies from companies including Eisai Co. and Biogen Inc. gain regulatory approvals and market adoption.
For ALZpath, the deal provides a commercialization pathway through one of the world's largest diagnostics companies. Financial terms of the licensing agreement were not disclosed. The partnership allows ALZpath to leverage Abbott's manufacturing capabilities, regulatory expertise, and commercial infrastructure rather than building its own sales network.
The licensing agreement marks the latest collaboration in the Alzheimer's diagnostics space, where companies including Roche Holding AG and Eli Lilly & Co. are developing blood-based tests. Roche has been developing its Elecsys beta-amyloid and pTau assays, while Lilly has invested in diagnostic tools to support its Alzheimer's drug portfolio.
Abbott's diagnostics business, one of the largest in the world, has been expanding its presence in neurology testing. The company already offers tests for various neurological conditions through its Alinity and Architect instrument platforms, which are installed in thousands of laboratories worldwide.
This article is for informational purposes only and does not constitute investment advice.
